EUVIMED · CrossrefZeitschrift
Drug Metabolism and Disposition
ISSN 0090-9556 · Elsevier BV
Neueste Artikel
Cyclical heat strain alters the function of hepatic cytochrome P450 enzymes in rats
Species differences in loxoprofen reductase activities: Roles of aldo-keto and carbonyl reductases in humans and rats
Corrigendum to “Clopidogrel–indobufen conjugates as dual antiplatelet prodrugs with enhanced bioactivation and synchronized pharmacokinetic–pharmacodynamic profiles in rats” [Drug Metabolism and Disposition 54 (2026) 100212]
A previously undetected major circulating metabolite of trazpiroben revealed by human radiolabeled absorption, distribution, metabolism, and excretion study
Multidimensional regulation of the cytochrome P450 metabolic network in pulmonary arterial hypertension: Homeostatic imbalance, pathological drivers, and environmental interactions
Absorption, distribution, metabolism, excretion, and pharmacokinetics of remibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, in healthy participants at steady state
Review of the selectivity of chlorzoxazone 6-hydroxylation as a probe for human cytochrome P450 2E1
Absorption, distribution, metabolism and excretion of sepiapterin, a natural precursor of tetrahydrobiopterin
Absorption, distribution, metabolism, and excretion of the BMS-986365 ligand-directed degrader diastereomers, R,R-[14C]BMS-986409 and R,S-[14C]BMS-986410, following oral administration in combination with an intravenous microtracer in healthy male participants
Investigation of the Nonlinear Pharmacokinetics of Vismodegib in Humans: Using PBPK Modeling to Examine Contributions of Saturable Plasma Protein Binding and Nonsink Permeation
Physiologically Based Pharmacokinetic Model Incorporating Enterohepatic Circulation of Multi-kinase Inhibitor Regorafenib to Explain Prolonged Exposure After Single and Repeated Dosing
Quantitative determination of lysosomal accumulation fraction, flyso, for estimating Kp,uu,brain tumor and target coverage for drugs treating human glioblastoma
Systematic search on fat free mass and fat mass in exclusively breastfed infants until one year of age – a contribution from the ConcePTION project
Full Mass Spectrum Background Subtraction in LC–HRMS Drug Metabolite Profiling: Untargeted Detection, Integrated Structural Characterization, and Applications
Persistent activation of growth hormone contributes to sexual dimorphic expression of hepatic drug metabolizing enzymes in Fgf15 transgenic mice
Absorption, metabolism, and excretion of single dose oral [14C]camizestrant in healthy human female participants
High-level expression of full-length human CYP2E1 in Escherichia coli: Comparison of full-length human CYP2E1 to truncated counterpart shows enhanced association with redox partners
Clinical discovery of anti-CYP2E1 autoantibodies and preclinical efficacy of a CYP2E1 inhibitor in rheumatoid arthritis
An in vitro approach to predict idiosyncratic drug-induced agranulocytosis using myeloperoxidase-derived reactive metabolites
Mechanistic prediction of apixaban and rivaroxaban secretion into human milk and infant systemic exposure through an integrated physiologically based pharmacokinetic framework
Evaluating alterations in drug-metabolizing enzymes in cancer: insights from in vivo, in vitro, and biomarker studies
Impact of the gut microbiome on hepatic cytochrome P450 3A4 (CYP3A4) in humanized pregnane X receptor-constitutive androstane receptor-CYP3A4/3A7 mice
Overlooked aspects of scaling enzyme activity through abundance across tissues and individuals: Insights from kcat measurements in matched liver and intestinal samples
Venlafaxine upregulates cortical catechol-O-methyltransferase expression and activity in rats and mice
Identification, synthesis, and characterization of a unique N-glucuronide of an acid metabolite of camizestrant (AZD9833) in humans
Drug-drug interaction by metabolites: Challenges and solutions during therapeutics innovation
P-glycoprotein-mediated impairment of doxorubicin clearance in inflammatory bowel disorders: Mechanistic insights from rat studies and whole-body physiologically based pharmacokinetic modeling
Drug-drug interaction assessments of clinical transporter inhibition: Learnings from the Transporter Working Group of the International Consortium for Innovation and Quality in Pharmaceutical Development
Mechanism-guided untargeted-to-targeted lipidomics identifies phosphatidylcholine 38:4 in rat bile as an Abcb4/Mdr2 inhibition marker
Enzyme-substrate-inactivator complex formation can impact time-dependent inhibition kinetics
Jahrgänge
2026 · 1752025 · 1962024 · 1752023 · 1922022 · 1742021 · 1252020 · 1682019 · 1732018 · 2312017 · 1842016 · 2552015 · 2562014 · 2762013 · 2782012 · 3122011 · 3282010 · 3442009 · 3502008 · 3682007 · 3562006 · 3322005 · 2882004 · 2452003 · 2412002 · 2542001 · 252000 · 2571999 · 2521998 · 381997 · 401996 · 2551995 · 2731994 · 1761993 · 2051992 · 1811991 · 2041990 · 1941989 · 1261988 · 1641987 · 157
EUVIMED